Member Info for ratcliffewriter

They probably do a nice line in baked hedgehog as well. And tarmac on drives....

I would say to look at his track record (people's track records and history are always worth scrutinising) and decide if he would waste his and his associates' time and his employers' money on something that was on the wane as today's bb 'experts' suggested. It's all opinion in the end, but facts and common sense seem to say that his faith in SCIB1 in combination is consistent and reassuring. And bear in mind he has had four years to monitor it and the people behind it - if any cracks were appearing they would be more evident than on first association.

Just thinking - if the bar really had been raised to an unrealistic level for Scancell during the wait for the combo trial to start, they would have had a perfect excuse to scale it down by not reapplying for the IND and just doing the trial in Europe, or even cancel it altogether using the rejected IND as an excuse , but they have done quite the opposite and returned for the successful IND application in (for pharma trials) a short space of time. Also, Keith Flaherty remains the clinical advisor and as much 'hands on' as ever. Does anyone seriously believe a man of his standing and dedication to curing cancer would remain committed to the SCIB1 trial out of charity and obligation to a project that was doomed to fall short? This is a far greater positive than the 'counterbalancing' negative of a punter who sold 200k shares when he has a track record of either spouting false 'close to the source' information on 'dead certs' or being hoodwinked by his 'inside source' - deliberately posting things known not to be the case, or victim of a con - it's one or the other! Today's negatives have been typically spontaneous and implausible, full of 'I read somewhere' myths legends rather than looking at the real facts and making a balanced judgement.

So a net 10 percent gain. Nice ass, as they say.

Interesting thought Balerno, but I would think the timing of the IND approval is entirely coincidental to the presentation tomorrow, but it is very convenient if nothing else.

Not just 5 years of frustration crumbs, but 5 years of every possible rival being developed and pushed, but KF is still backing SCIB1. That's a good endorsement imo.

On Friday they said in the interims RNS - 'The Company is now actively pursuing a new IND application for SCIB1 in the US and will update the market on the outcome of the FDA's review in due course.' On Monday they announce the approval. Tall about playing their cards close to their chest. It proves that news really can come at any time.

Knowlesi - Not a good RNS for you is it? The better than expected funding status has rather taken the wind out of your sails as far as a cry of 'imminent placing' is concerned, and the time period proposed for the start of the Moditope trial seems to be unchanged, so why did you imply this morning that 'H2' is different to 'latter half of the calendar year.'

Maybe not as close to being in the loop as he thought then.

Imo a sell, but the price to sell has risen gently this morning so possibly a buy to come. We shall see.

I see the 271,576 trade from yesterday appears to have been cancelled immediately it was placed, but not disclosed until today.

Not forgetting the breadth of patent cover (the 'land grab') that way exceeded the scope that Scancell ever thought they'd get.

Opinions would be polarised. But then that's nothing new here!!

I suspect that would get a cool reception.

Twice...

Indeed so - September, then December, then January. How long till the next one...or two...or more?

Scancell has retweeted this, which was tweeted by Lee Marchado (or however you spell it). Food for speculation anyway. https://www.sciencedirect.com/science/article/pii/S1044532320300099

I used to READ A CHAT BOARD where capitals get USED QUITE a lot by CERTAIN posters but I THINK THAT POSTER has a number of mental ISSUES TO BE honest.

...but probably greater than others would have you think.

Like others, he wanted to aim big.